<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304317</url>
  </required_header>
  <id_info>
    <org_study_id>0405M60562</org_study_id>
    <secondary_id>3485B</secondary_id>
    <nct_id>NCT00304317</nct_id>
  </id_info>
  <brief_title>Celecoxib (Celebrex) in the Management of Acute Renal Colic</brief_title>
  <official_title>Celecoxib in the Management of Acute Renal Colic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to quantify the amount Celebrex, a specific cyclooxygenase-2&#xD;
      (COX-2) inhibitor, when used for the management of acute renal colic for a ureteral stone&#xD;
      will:&#xD;
&#xD;
        -  reduce pain medication usage&#xD;
&#xD;
        -  improve the percentage of spontaneous stone passage&#xD;
&#xD;
        -  decrease the time to spontaneous passage, and&#xD;
&#xD;
        -  shift the size distribution of stones passed towards larger sizes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted as a prospective, randomized, double-blind controlled clinical&#xD;
      trial. One-hundred and fifty-four patients with symptoms of acute renal colic and a ureteral&#xD;
      calculus less than 10 mm in largest diameter on flat plain abdominal x-ray (KUB) or&#xD;
      non-contrast computer tomography (CT) scan will be randomized in this trial. At the time of&#xD;
      presentation with acute renal colic to the Emergency Department, the patient will be&#xD;
      recruited for involvement. After informed consent, patients will be provided either 200 mg of&#xD;
      Celebrex or a placebo equivalent. They will be instructed to follow the recommended dosing&#xD;
      regimen for acute pain, taking two tablets in the emergency room (400 mg), followed by one&#xD;
      tablet 12 hours later (200 mg), then one tablet twice a day for 10 days. Patients will be&#xD;
      provided a prescription for Vicodin (1-2 tablets of 5/500 every 4-6 hours) to be taken as&#xD;
      required for pain. Throughout the study, patients will be asked to strain urine for passage&#xD;
      of calculus and note date and time of passage. Patients will also be asked to maintain a&#xD;
      daily narcotic diary and complete a daily pain analog scale provided by our institution.&#xD;
      Patients will be followed in the Urology Department's Stone Clinic with weekly imaging&#xD;
      studies (KUB or CT scan) and renal function tests (serum creatinine) for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI is no longer at the University of Minnesota&#xD;
  </why_stopped>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in narcotic usage</measure>
    <time_frame>at 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in the percentage of spontaneous stone passage</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shift in the size distribution of stones passed towards larger sizes</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in the time to spontaneous passage</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ureteral Calculi</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celecoxib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.</description>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ureteral calculus &lt;= 10 mm in largest diameter&#xD;
&#xD;
          -  Patient elects conservative management over immediate surgical intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Solitary kidney&#xD;
&#xD;
          -  Renal insufficiency (creatinine [CR] &gt; 1.8)&#xD;
&#xD;
          -  Urinary infection (fever &gt; 101 degrees Fahrenheit, positive urine culture, many&#xD;
             bacteria on urinalysis)&#xD;
&#xD;
          -  Allergic-type reactions to sulfonamides&#xD;
&#xD;
          -  Patients with known hypersensitivity to celecoxib&#xD;
&#xD;
          -  Patients who have experienced asthma, urticaria, or allergic-type reactions after&#xD;
             taking aspirin or nonsteroidal anti-inflammatory agents (NSAIDs)&#xD;
&#xD;
          -  Prior history of gastrointestinal (GI) bleed or active gastric ulcer disease&#xD;
&#xD;
          -  Pregnancy/nursing&#xD;
&#xD;
          -  Moderate-severe hepatic dysfunction (Child-Pugh Classification B or C)&#xD;
&#xD;
          -  Concomitant use of drugs that inhibit P450 2C9, drugs metabolized by P450 2D6, ACE&#xD;
             inhibitors, furosemide, warfarin (and other anticoagulants, not including low-dose&#xD;
             aspirin), fluconazole, or lithium&#xD;
&#xD;
          -  Women of child-bearing age unwilling to use effective contraception for the duration&#xD;
             of the trial.&#xD;
&#xD;
          -  Significant or unstable cardiovascular disease defined as:&#xD;
&#xD;
               -  myocardial infarction or stroke less than 3 months prior to the study&#xD;
                  randomization&#xD;
&#xD;
               -  planned revascularization (percutaneous coronary intervention [PCI] or coronary&#xD;
                  artery bypass surgery [CABG]) at the time of study screening&#xD;
&#xD;
               -  angina at rest or uncontrolled angina&#xD;
&#xD;
               -  hospitalization or emergency department visits for cardiac-related illness less&#xD;
                  than 3 months prior to randomization&#xD;
&#xD;
               -  uncontrolled hypertension (defined as systolic blood pressure [BP] &gt; 140 mmHg&#xD;
                  and/or diastolic BP &gt; 90 mmHg at the baseline visit)&#xD;
&#xD;
               -  evidence of cardiac electrophysiologic instability including history of&#xD;
                  uncontrolled complex ventricular arrhythmia, uncontrolled atrial fibrillation or&#xD;
                  flutter, or uncontrolled supraventricular tachycardias with a ventricular&#xD;
                  response heart rate of &gt; 100 beats per minute (BPM) at rest. (Subjects whose&#xD;
                  cardiac electrophysiologic instability is controlled with a pacemaker or&#xD;
                  implantable cardioverter defibrillator (ICD) are eligible.)&#xD;
&#xD;
               -  symptoms, signs or treatment for congestive heart failure (CHF) or known left&#xD;
                  ventricular dysfunction with ejection fraction &lt; 40%&#xD;
&#xD;
               -  undergone coronary bypass surgery or any major surgery (cardiac or noncardiac) or&#xD;
                  trauma within the past 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manoj Monga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>March 16, 2006</study_first_submitted>
  <study_first_submitted_qc>March 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>calculi</keyword>
  <keyword>ureteral calculi</keyword>
  <keyword>ureter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Renal Colic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

